Baxter International Inc. Q1 2008 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2008. Baxter International Inc. operates in three primary segments: BioScience, Medication Delivery, and Renal. The company is a large accelerated filer incorporated in Delaware. As of April 30, 2008, there were 627,379,237 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $2,877 million | $2,675 million |
| Net Income | $429 million | $403 million |
| Diluted EPS | $0.67 | $0.61 |
| Gross Margin | 48.0% | 47.3% |
| Operating Cash Flow | $362 million | $215 million |
| Cash and Equivalents | $1,736 million | $2,384 million |
| Total Debt (Short + Long Term) | $2,872 million | $3,089 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% year-over-year. Excluding the divested Transfusion Therapies (TT) business, sales grew 10%, driven by a 6 percentage point favorable impact from foreign currency fluctuations (weakening U.S. Dollar).
- Profitability: Net income rose 6% to $429 million. The effective tax rate decreased to 19.7% from 23.8% in the prior year, as the 2007 rate was elevated by the tax impact of the TT divestiture gain.
- Segment Performance:
- BioScience: Sales up 5%; Pre-tax income up 21% due to strong sales of ADVATE and liquid IGIV.
- Medication Delivery: Sales up 8%; Pre-tax income down 40% due to significant charges (see below).
- Renal: Sales up 6%; Pre-tax income down 17% due to the loss of a government tender in Mexico.
- Cash Flow: Operating cash flow increased significantly to $362 million. However, cash and equivalents decreased by $803 million primarily due to $545 million in stock repurchases and $157 million in capital expenditures.
Guidance, Risks, and Unusual Items
- Unusual Charges: The Medication Delivery segment recorded $72 million in charges during Q1 2008:
- COLLEAGUE Infusion Pumps: A $53 million charge ($39 million cash, $14 million asset impairment) due to delays in remediation and software modifications.
- Heparin Recall: A $19 million charge ($5 million cash, $14 million asset impairment) related to the recall of heparin sodium injection products due to adverse reactions.
- Restructuring: The company utilized $12 million of restructuring reserves in Q1 2008. Remaining reserves of $69 million are expected to be utilized by the end of 2009.
- Legal and Regulatory Risks:
- COLLEAGUE Pumps: Shipments remain held in the U.S. pending FDA approval of remediation steps under a Consent Decree.
- Heparin: Approximately 20 lawsuits filed alleging adverse reactions; cases are in early stages.
- Patent Litigation: Ongoing disputes regarding ADVATE, Sevoflurane, and Peritoneal Dialysis patents.
- Medicare/Medicaid Pricing: Subject to investigations and lawsuits regarding average wholesale price reporting.
- Outlook: Management anticipates an effective tax rate of approximately 19% to 19.5% for 2008. The company has $2.6 billion remaining under share repurchase authorizations.
Investor Verification Checklist
- Regulatory Resolution: Monitor FDA progress on the COLLEAGUE infusion pump recommercialization and the status of the heparin recall litigation.
- Charge Adequacy: Verify if the $97 million remaining reserve for COLLEAGUE pumps and $5 million for heparin are sufficient given ongoing remediation delays.
- Currency Impact: Assess the sustainability of sales growth given the 6 percentage point favorable foreign currency impact in Q1 2008.
- Debt Maturities: Review the repayment schedule for long-term debt, noting the recent repayment of $250 million in notes in February 2008.
- Segment Mix: Evaluate the long-term margin impact of the Medication Delivery segment's recurring charges versus the high-margin growth in BioScience.